Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LIQ861

Small molecule · developed by Liquidia Technologies

Phase 3 Most advanced trial
LQDA Developer
3 Registered trials

What is LIQ861?

LIQ861 is an inhaled dry powder formulation of treprostinil, delivered as capsules in strengths of 25, 50, 75 and 100 μg. It is studied in pulmonary hypertension and interstitial lung disease, with single-dose use in the acute setting and four-times-daily dosing in the chronic setting.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Respiratory
Developer
Liquidia Technologies, Inc. (LQDA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03992755 Phase 3 Primary Pulmonary Hypertension Active not recruiting LQDA
NCT03884465 Phase 2 Pulmonary Arterial Hypertension Terminated LQDA
NCT06129240 N/A Pulmonary Hypertension Active not recruiting LQDA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Interstitial Lung DiseasePrimary Pulmonary HypertensionPulmonary HypertensionPulmonary Arterial Hypertension

More from Liquidia Technologies

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LQDA page.

Follow LQDA, the company behind LIQ861

See LQDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LQDA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.